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The 2009 European Guidelines on Diagnosis and Treatment of Pulmonary Hypertension have been adopted
for Germany. The guidelines contain detailed recommendations on the diagnosis of pulmonary hypertension
(PH). However, the practical implementation of the European Guidelines in Germany requires the consider-
ation of several country-speciﬁc issues and already existing novel data. This requires a detailed commentary
to the guidelines, and in some aspects an update already appears necessary. In June 2010, a Consensus Con-
ference organized by the PH working groups of the German Society of Cardiology (DGK), the German Society
of Respiratory Medicine (DGP) and the German Society of Pediatric Cardiology (DGPK) was held in Cologne,
Germany. This conference aimed to solve practical and controversial issues surrounding the implementation
of the European Guidelines in Germany. To this end, a number of working groups was initiated, one of which
was speciﬁcally dedicated to the treatment of pulmonary arterial hypertension (PAH). This commentary de-
scribes in detail the results and recommendations of the working group on treatment of PAH which were last
updated in October 2011.
© 2011 Elsevier Ireland Ltd. All rights reserved.
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This article is part of a supplement of the International Journal
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pulmonary hypertension are described that took place in June 2010
in Cologne, Germany, and was organized by the PH working groups
of the German Society of Cardiology (Deutsche Gesellschaft für
Kardiologie, DGK), the German Society of Respiratory Medicine
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(Deutsche Gesellschaft für Pneumologie, DGP) and the German
Society of Pediatric Cardiology (Deutsche Gesellschaft für pädi-
atrische Kardiologie, DGPK). This conference addressed practical
issues surrounding the implementation of the European Guidelines
for diagnosis and therapy of pulmonary hypertension in Germany.
To this end, a number of working groups was initiated, one of which
was speciﬁcally dedicated to the treatment of pulmonary arterial
hypertension (PAH). The authors were members of this working
group. The corresponding articles were initially published in the
Deutsche Medizinische Wochenschrift, and the information was now
updated in October 2011. Below, the corresponding sections of the
European Guidelines are described [1–3] whereby comments and
additions appear in italics. The information on class of recommen-
dation and level of evidence correspond to the tables listed in the
preamble of this supplement.
1. Introduction
In the past few years, treatment of PAH has undergone an
extraordinary evolution, which has led to the current approval by
regulatory agencies of seven targeted PAH drugs with different
routes of administration. The approval of additional drugs is ex-
pected in the near future. Modern drug therapy leads to a signiﬁcant
improvement in patients’ symptomatic status and a slower rate of
clinical deterioration. In addition, a meta-analysis performed on
23 randomized controlled trials (RCTs) in PAH patients (published
prior to October 2008) reports a 43% decrease in mortality and a
61% reduction in hospitalizations in patients treated with speciﬁc
drug therapies vs. patients randomized to placebo [4]. These results,
achieved after an average treatment period of 14.3 weeks, support
the eﬃcacy of the currently approved PAH treatments. Despite this
ﬁnding, PAH remains a chronic disease without a cure. In addition,
the medical and interventional treatments for more advanced cases
are still invasive (e.g. continuous parenteral prostanoid therapy)
and prone to signiﬁcant side effects [1,2].
The therapy of PAH patients cannot be considered as a mere
prescription of drugs but is characterized by a complex inter-
disciplinary strategy which includes the evaluation of severity,
supportive and general measures, the assessment of vasoreactiv-
ity, the estimation of eﬃcacy, and combination of different drugs
plus interventions (e.g. atrial septostomy, transplantation). In any
of these steps, the knowledge and experience of the responsible
physicians are critical to optimize the available resources [1,2].
Comment:
In light of the high costs of targeted PAH therapies, the consideration
of cost eﬃcacy is of relevance. However, when treating patients
with a life-threatening disease, medical necessities must always be
paramount.
In this context, it is crucial to ensure a proper diagnostic work-up
and classiﬁcation, and to prescribe targeted PAH therapies within the
approved indication and meet the requirements of each individual
patient. It is the responsibility of PH expert centers to ensure this.
2. General measures
Psychosomatic or psychological as well as social work support
are important for patients with PAH as is the case in all chronic
diseases. Encouraging patients and their family members to join
patients support groups (in Germany “pulmonale hypertonie e.V.
[phev]”) can have positive effects on coping, conﬁdence, and
outlook [1,2].
Although patients should be encouraged to be active within
symptom limits, excessive physical activity that leads to distressing
symptoms (e.g., severe breathlessness, exertional dizziness, chest
pain, syncope, etc.) should be avoided. On the other hand, there
Table 1
Recommendations for general measures [1,2].
Statement Class of recom-
mendation
Level of
evidence
It is recommended to avoid pregnancy in
patients with PAH
I C
Immunization of PAH patients against
inﬂuenza and pneumococcal infection is
recommended
I C
Physically deconditioned PAH patients should
be considered for supervised exercise
rehabilitation
IIa B
Psychosocial support should be considered in
patients with PAH
IIa C
In-ﬂight O2 administration should be
considered for patients in WHO-FC III and IV
and those with arterial blood O2 pressure
consistently less than 8 kPa (60 mmHg)
IIa C
Epidural anaesthesia instead of general
anaesthesia should be utilized, if possible, for
elective surgery
IIa C
Excessive physical activity that leads to
distressing symptoms is not recommended in
patients with PAH
III C
is growing evidence for the value of supervised physical training
programs in improving exercise performance [5,6]. Physically de-
conditioned patients may therefore undertake supervised exercise
rehabilitation. This should however only take place in facilities that
are specially trained in PAH, and this approach requires further
scientiﬁc exploration [1,2].
Patients with PAH should avoid pregnancy. Appropriate consul-
tation and reliable contraception is necessary whereby pharmaco-
logical interactions with PAH drugs that may affect the eﬃcacy of
hormonal contraceptives must be pointed out.
Travelling to altitudes above 1,500–2,000 m without supplemen-
tal O2 should be avoided. During air travel, the known physiological
effects of hypoxia suggest that in-ﬂight O2 administration should
be considered for patients in WHO functional class III and IV and
those with arterial blood O2 pressure consistently below 8 kPa (60
mmHg). A ﬂow rate of 2 L/min will raise inspired O2 pressure to
values seen at sea level [1,2] (see comment*).
Regular immunizations against inﬂuenza and pneumococcal
infections are recommended [1,2].
Elective surgery is expected to have an increased risk in patients
with PAH. It is not clear as to which form of anaesthesia is
preferable but epidural is probably better tolerated than general
anaesthesia [1,2].
Comment:
The risk of severe complications during and after pregnancy is
particularly high in IPAH/HPAP, and considerable in Eisenmenger’s
syndrome. The level of endangering depends, among others, on the
extent of pulmonary hypertension and may be highest in patients in
whom pulmonary artery pressure exceeds half-systemic pressure. Exact
cut-off values are not known. In PH due to a left-to-right shunt, the
hazard level depends on the size of the shunt, the (dys)function of
the affected parts of the heart, and the risk of paradox embolism. In
such cases, shunt closure should be considered before pregnancy. The
few cases of uncomplicated pregnancies in patients with IPAH/HPAH
or with Eisenmenger’s syndrome should not be reason to diverge from
the general recommendation to avoid pregnancy in women with severe
pulmonary hypertension.
Supervised exercise training with adjusted physical strain by a
highly qualiﬁed team in a specialized rehabilitation center has been
evaluated by a German working group and showed a signiﬁcant
improvement of exercise capacity at 3 months [5]. There is also recent
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evidence of the safety and long-term eﬃcacy of the training program.
However, is has so far not been investigated if a generalization and
the safe application outside of these special conditions is warranted.
Furthermore, it remains unclear if controlled physical training –
beyond its effects on clinical symptoms – leads to an improvement of
survival and/or hemodynamics. Prospective studies investigating this
are currently under way.
Depression considerably impairs the quality of life of PAH patients,
is associated with inadequate patient behavior, and may have a neg-
ative effect on adherence and the course of the disease. Psychological
comorbidity (especially depression, anxiety and adjustment disorders)
should therefore be documented on a routine basis by the use of
screening questions or questionnaires. The following two screening
questions may be appropriate to appraise the danger to the patient
from depression with high sensitivity and speciﬁty [7]:
• “Did you frequently suffer from feelings of dejection, depression, or
hopelessness in the past month?”
• “Did you frequently suffer from lack of interest or joylessness in the
past month?”
One available questionnaire is e.g. the German version of the “Hospital
Anxiety and Depression Scale” (HADS-D), representing an economic
instrument that is especially suited for patients with physical illnesses.
Patients should be offered focused psychotherapy and/or pharmacolog-
ical antidepressive treatment [8].
Elective surgical interventions should always be performed in close
cooperation with specialized PH centers. Epidural anaesthesia may
lead to loss of vascular tone in the lower extremities which has
negative impact on venous return and systemic pressure, and may
therefore lead to shunt reversal in the respective patients. Therefore,
conduction anesthesia should only be carried out by experienced
physicians, and potential complications must always be considered.
General anaesthesia may be beneﬁcial in individual cases.
*Air travel: It should be emphasized that the evidence for the
recommendations given in the ESC/ERS guidelines is rather low.
Patients with shunt-related hypoxemia seem to react less sensitive
to hypoxia than those with pulmonary hypoxemia. The sensitivity of
hypoxemia caused by pulmonary vascular disease is not known. A
recently conducted survey in more than 720 patients in Germany
(supported by the German patient organization [phev]) demonstrated
good safety (no adverse events) during air travel in patients with
stable pulmonary vascular disease. 29 of 57 patients on outpatient
oxygen therapy used oxygen during the ﬂight [9]. Further international
prospective studies will be required in order to make appropriate
recommendations.
3. Supportive therapy
3.1. Oral anticoagulants
Despite insuﬃcient available data, oral anticoagulation is rec-
ommended in PAH patients unless there are contraindications.
Evidence in favour of oral anticoagulation is conﬁned to patients
with IPAH, HPAH, and PAH due to anorexigens; it is generally
retrospective and based on single center experience [1,2]. Hence,
a class IIa recommendation is given for oral anticoagulation in
IPAH, heritable PAH, and PAH due to anorexigens, and a class
IIb recommendation is given for patients with APAH (Table 2).
The recommended target INR is 2.0–3.0. (Special recommendations
for patients with Eisenmenger’s syndrome and portopulmonary
hypertension are listed in Tables 7 and 9).
3.2. Diuretics
Although there are no randomized controlled trials of diuretics
in PAH, clinical experience shows clear symptomatic beneﬁt in
ﬂuid-overloaded patients treated with this therapy. Therefore,
Table 2
Recommendations for supportive therapy [1,2].
Statement Class of recom-
mendation
Level of
evidence
Diuretic treatment in PAH patients with signs
of right ventricular failure and ﬂuid retention
I C
Continuous long-term oxygen therapy is
indicated in PAH patients when arterial blood
O2 pressure is consistently <8 kPa (60
mmHg) a
I C
Oral anticoagulant treatment should be
considered in patients with IPAH, heritable
PAH, and PAH due to use of anorexigens
IIa C
Oral anticoagulant treatment can be
considered in patients with APAH
IIb C
Digoxin may be considered in patients with
PAH who develop atrial tachyarrhythmias to
slow ventricular rate
IIb C
a See also recommendations for PAH associated with congenital cardiac shunts
(Table 9).
diuretics are used according to the clinical situation. Since there is
no data for the superiority or inferiority of individual substances,
the choice and dose of diuretic therapy may be left to the PAH
physician. The addition of aldosterone antagonists should also be
considered [1,2].
3.3. Oxygen
The guidance with regard to long-term oxygen therapy in
patients with PAH is mainly based on evidence in patients with
COPD: When arterial blood O2 pressure is consistently less than 8
kPa (60 mmHg) patients are advised to take O2 to achieve an arterial
blood O2 pressure of >8 kPa for at least 15 h/day. Ambulatory O2
may be considered when there is evidence of symptomatic beneﬁt
and correctable desaturation on exercise [1,2]. Since there are no
randomized data to suggest that long-term O2 therapy is beneﬁcial
in patients with PAH, the decision for O2 therapy has to be made
on an individual basis.
3.4. Treatment of arrhythmias
The ECS/ERS guidelines include only a brief comment about
the use of digoxin for the treatment of atrial tachyarrhythmias to
slow ventricular rate. This, however, does not adequately meet the
requirements of many patients (see comment).
Comment:
Diuretic therapy may also be indicated for the prevention of right
ventricular failure and ﬂuid retention. The indication for the use of
diuretics is often based on the central venous pressure measured
during right heart catheterization. Furthermore, peripheral edema in
the lower extremities, concomitant pleural and/or pericardial effusion
as well as ascites represent clinical signs that are indicative for diuretic
therapy. While there is no general recommendation as to which class
of diuretics should be used, low to moderate doses of aldosterone
antagonists are mostly combined with loop diuretics.
The indication for long-term O2 treatment in Eisenmenger’s syn-
drome is controversial. Adults with Eisenmenger’s syndrome usually do
not beneﬁt from such treatment, and the risks and side effects (e.g.
exsiccosis of the nasal mucosa, tendency to epistaxis, sleep disorders)
must be considered. In such cases, O2 treatment should be limited to
individual patients who subjectively beneﬁt from this treatment or to
special situations (e.g. pulmonary infections).
While ventricular tachycardia is rather uncommon in patients with
PAH, supraventricular tachycardia – especially atrial ﬂutter/ﬁbrillation
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– occurs more frequently. Even when the ventricular rate remains
normal, such arrhythmias usually lead to signiﬁcant clinical worsening
and progressive right ventricular failure if left untreated [10]. These
patients beneﬁt from aggressive therapy, aiming at restoring sinus
rhythm. Even though the available data for treating these arrhythmias
in PAH is sparse, restoring or maintaining the sinus rhythm should
be attempted whenever possible. Medical treatment with amiodarone
or interventional techniques (ablation) may be indicated. Although β-
blockers and calcium channel blockers bear risks due to their negative
inotropic effects, they may be indicated in individual cases.
Current data demonstrate that the presence of anemia and iron de-
ﬁciency in patients with pulmonary hypertension correlates negatively
with disease severity and all-cause mortality [11,12]. Therefore, appro-
priate replacement therapy may be helpful – similar as reported for
patients with left heart failure. However, the available data for patients
with pulmonary hypertension should be regarded as preliminary, and
further data must be collected, especially with regard to therapeutic
consequences.
4. Targeted PAH drug therapy
Regarding targeted PAH drug therapy, only the most important
aspects of individual therapies are described in this manuscript. For
detailed information please refer to the European guidelines and
to specialized literature [1–3,13–27]. The recommended use of the
available agents is demonstrated in a treatment algorithm in Fig. 1
[1,2]. The grades of recommendation and the levels of evidence
for the individual PAH treatments are also shown in Table 3.
Country-speciﬁc regulatory approval and labeling for PAH medical
treatments are listed in Table 4.
Comment:
The approval for inhaled treprostinil was given in 2009 by the FDA
but denied in 2010 by the EMA. Therefore, this drug is currently only
available in the USA.
5. Calcium channel blockers
Calcium channel blockers (CCB) are recommended only for PAH
patients (not for other forms of PH) who demonstrate a favourable
response to acute vasodilator testing at the time of right heart
catheterization and meet the deﬁned responder criteria (see article
on invasive diagnosis of PH in this Supplement). It is increasingly
recognized that one a small number of patients with IPAH meet
the responder criteria and do well with CCBs [28,29]. Patients who
have not undergone a vasoreactivity study or those with a negative
study should not be started on CCBs because of potential severe
side effects (e.g. hypotension, syncope, RV failure) [1,2]. Therefore,
treatment with CCBs should only be initiated at centers with
comprehensive experience with PAH patients, since this therapy
may have fatal consequences if not indicated.
The CCBs that have been predominantly used in reported studies
are nifedipine, diltiazem, and amlodipine, with particular emphasis
on the ﬁrst two [28,29]. The daily doses of these drugs that
have shown eﬃcacy in IPAH are relatively high (120–240 mg for
nifedipine, 240–720 mg for diltiazem, up to 20 mg for amlodipine).
CCBs should be started at a low dose and up-titrated cautiously
to the maximum tolerated dose. Limiting factors for dose increase
are usually systemic hypotension and lower limb peripheral edema.
If a patient does not show an adequate response (deﬁned as
being in WHO functional class I or II and marked hemodynamic
improvement), additional PAH therapy should be instituted [1,2].
Comment:
Although most data is available for nifedipine and diltiazem, most
PH centers in Germany predominantly use amlodipine. The initial dose
Table 3
Recommendations for the eﬃcacy of speciﬁc PAH drug therapy, balloon atrial
septostomy, and lung transplantation for PAH (group 1) according to WHO
functional class [1,2] #.
Measure WHO-FC WHO-FC WHO-FC
II III IV
Calcium channel I-C a I-C a –
blockers
Endothelin receptor Ambrisentan I-A I-A IIa-C
antagonists Bosentan I-A I-A IIa-C
Phosphodiesterase Sildenaﬁl I-A I-A IIa-C
type-5 inhibitors Tadalaﬁl I-B I-B IIa-C
Prostanoids Beraprost – IIb-B –
Epoprostenol (iv) – I-A I-A
Iloprost (inhaled) – I-A IIa-C
Iloprost (iv) – IIa-C IIa-C
Treprostinil (sc) – I-B IIa-C
Treprostinil (iv) – IIa-C IIa-C
Treprostinil (inhaled) b – I-B IIa-C
Primary combination – – IIa-C
therapy
Sequential combination – I-C I-C
therapy
Balloon atrial septostomy – I-C I-C
Lung transplantation – I-C I-C
a Only in responders to acute vasoreactivity tests. Recommendation class I for
idiopathic PAH, heritable PAH, and PAH due to anorexigens; IIa for APAH.
b Not approved by the EMA.
# Since the ERA sitaxentan has been withdrawn from the market, this compound
has been removed from the original ESC/ERS table.
Table 4
Country-speciﬁc regulatory approval and labeling for PAH-speciﬁc drug therapy
[1,2] #.
Treatment Country Etiology WHO-FC
Calcium channel blockers – – –
Ambrisentan USA, Canada, EU PAH II–III–IV
Bosentan a EU PAH II–III
USA, Canada PAH II–III–IV
Sildenaﬁl USA, Canada PAH II–III–IV
EU PAH II–III
Tadalaﬁl USA PAH II–III–IV
EU PAH II–III
Beraprost b Japan, Korea PAH II–III–IV
Epoprostenol (iv) c EU PAH III–IV
Iloprost (inhaled) EU IPAH III
USA PAH III–IV
Iloprost (iv) New Zealand IPAH, PAH-CTD, CTEPH III–IV
Treprostinil (sc) USA PAH II–III–IV
Canada PAH III–IV
EUd IPAH III
Treprostinil (iv) USA e PAH II–III–IV
Treprostinil (inhaled) b USA PAH III
a Speciﬁcally approved also for PAH associated with congenital left-right shunts
and Eisenmenger’s syndrome.
b Not approved in Europe.
c Epoprostenol in Europe has not been centrally approved by the EMA but on a
national basis in several European countries (not in Germany).
d Treprostinil in Europe has not been centrally approved by the EMA but is
approved in France and other countries on a national basis through the mutual
recognition process.
e In case of intolerance of subcutaneous application.
CTD, connective tissue diseases; CTEPH, chronic thromboembolic pulmonary
hypertension; EMA, European Medicines Agency (European Approval Agency);
IPAH, idiopathic PAH; PAH: pulmonary arterial hypertension; WHO-FC: WHO
functional class.
# Since the ERA sitaxentan has been withdrawn from the market, this compound
has been removed from the original ESC/ERS table.
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Fig. 1. Evidence-based treatment algorithm for patients with pulmonary arterial hypertension (for group 1 patients only) [1,2] #.
* In order to reach a systemic arterial pO2 ≥8 kPa (60 mmHg) + EMA evaluation is pending. § IIa-C for WHO-FC II. APAH, associated PAH; IPAH, idiopathic PAH; BAS, balloon
atrial septostomy; LTX, lung transplantation; CCB, calcium channel blocker; ERA, endothelin receptor antagonist; PDE-5 I, phosphodiesterase type-5 inhibitor; WHO-FC,
WHO functional class (corresponds to modiﬁed NYHA class). Combination therapy = combination of 2 or more speciﬁc PAH therapies.
# Since the ERA sitaxentan has been withdrawn from the market, this compound has been removed from the original ESC/ERS treatment algorithm.
is 2.5 mg/day which – under careful monitoring – is increased to the
normal target dose of 10–20 mg/day within a few weeks. Currently,
it remains unclear how to use CCBs in patients who, although
meeting the responder criteria, present with severely compromised
right ventricular function (e.g. cardiac index <1.5 l/min/m2) at the
time of vasoreactivity testing. Upon initiation of CCB therapy, it is
conceivable that these patients could suffer right ventricular failure due
to the cardiodepressive potential of CCBs before they may beneﬁt from
the desired effect. In such cases, it should be considered to primarily use
one of the available targeted PAH therapies, and once right ventricular
function has improved and after repeat right heart catheterization
with vasoreactivity testing (provided that the responder criteria is still
met), to initiate CCB therapy. During up-titration it is recommended
to draw special attention to hypotension, obstipation, and any signs
of right heart failure. Peripheral edema can mostly be managed
with diuretics and/or compression stockings. PVOD patients meeting
responder criteria are particularly prone to lung edema on CCBs.
6. Endothelin receptor antagonists (ERA)
All approved compound belonging to this drug class (bosentan,
ambrisentan) are presumed potentially hepatotoxic and can only
be prescribed by registered prescribers. Regular controls of amino-
transferases (in 4-week intervals) are required. The speciﬁed target
doses for ERAs apply to adult patients; for children or patients <40
kg body weight, it is referred to the respective summary of product
characteristics and the section “special aspects concerning children”
(see below).
• Bosentan [16,18,22,25] is a dual endothelin-A and -B receptor
antagonist and is approved for the treatment of PAH in WHO
functional class II and III. The target dose is 125 mg b.i.d. In
children, bosentan is approved from the age of 2 years and is
also available in a special pharmaceutical form of 32-mg tablets
that can be quartered.
• Ambrisentan [21,30] is a selective endothelin-A receptor antago-
nist and is approved for the treatment of PAH in WHO functional
class II and III with a target dose of 5–10 mg once daily.
Comment:
So far only bosentan has been investigated in a randomized
controlled study with patients in functional stage II only, and demon-
strated signiﬁcant improvement of hemodynamics as well as a reduced
rate of clinical events even though it did not achieve one of the pre-
deﬁned primary endpoints, the improvement of the 6-minute walking
distance [22]. The European approval agency EMA evaluated the data
from this study as suﬃciently solid to also issue an indication for
bosentan for the treatment of PAH patients in functional class II. Even
if there is no such speciﬁc study for ambrisentan, the EMA decided
on the basis of subgroup analyses of class II patients from the ARIES
studies of ambrisentan, to initially issue approval also for functional
class II patients [21]. Data from a postmarketing surveillance in the
US showed no evidence of hepatotoxicity with the use of ambrisentan.
Accordingly, the FDA has removed the recommendation to perform
monthly transaminase controls in patients with ambrisentan therapy.
Sitaxentan [13,14] had also received approval by the EMA for the
treatment of PAH in WHO functional class III. However, in december
2010 this compound was withdrawn from the market worldwide
because of reported deaths that occurred most likely in association
with idiosyncratic liver toxicity. Such effects have not been reported for
other ERAs.
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7. Phosphodiesterase type-5 (PDE-5) inhibitors
• Sildenaﬁl [20,27] is approved for the treatment of PAH in
functional class II and III at a dose of 20 mg t.i.d. In children,
sildenaﬁl is approved at the age between 1 and 17 years.
• Tadalaﬁl [19] is approved for the same indication as sildenaﬁl.
The target dose for this compound is 40 mg once daily.
Comment:
There is consensus among the German PH experts that the currently
approved dose of 20 mg t.i.d. for sildenaﬁl should at times be exceeded
during the course of long-term therapy of PAH patients. This is based
on the clinical observation that patients, who initially show clinical
and hemodynamic improvement on the approved dose may then
deteriorate after a variable period of time. It is unclear, however,
if this worsening reﬂects progression of the underlying disease or a
beginning tolerance to the treatment with PDE-5 inhibitors. In many
cases, an escalation of the sildenaﬁl dose to up to 80 mg t.i.d.
results in further improvement of the clinical condition and pulmonary
hemodynamics. This observation is supported by published data. For
example, the relevant SUPER-1 study demonstrated a clear correlation
between the sildenaﬁl dose and the hemodynamic improvement of
examined patients (whereby 80 mg sildenaﬁl t.i.d. was most effective)
[20]. Furthermore, while there are no long-term eﬃcacy data available
for the 20 mg t.i.d. dose, by far most of the available long-term
data on sildenaﬁl were collected on PAH patients treated with 80 mg
t.i.d. (including 3-year long-term follow-up data from the SUPER-2
study [31]). Similarly, the PACES study, a randomized, controlled trial
on the combined use of intravenous prostacyclin and oral sildenaﬁl,
demonstrated for the ﬁrst time a survival beneﬁt in patients receiving
combination therapy including sildenaﬁl 80 mg t.i.d. as compared
to patients who continued treatment with intravenous prostacyclin
“only” [27]. While there is evidence for the use of sildenaﬁl at dosages
beyond the approved dose of 20 mg t.i.d. in selected PAH patients,
dose increases exceeding 20 mg t.i.d. should only take place at or after
consultation with a PH expert center.
For tadalaﬁl, the highest dose (40 mg once daily) tested in a clinical
development program (PHIRST study) has been approved [19]. Unlike
sildenaﬁl, there is no data in the available literature that would support
higher doses for the treatment of PAH patients.
The equivalent oral doses for these two PDE-5 inhibitors are
unknown.
A postmarketing surveillance in children with PAH showed in-
creased mortality in those children with doses beyond the approved
dose, and a warning letter has been issued. The reasons for the asso-
ciation between elevated doses and elevated mortality are a matter of
discussion.
Sildenaﬁl was recently approved by the EMA for intravenous use in
patients with PAH who are prescribed oral sildenaﬁl and are clinically
and hemodynamically stable, but are temporarily unable to take orally
applied medications.
8. Prostanoids
• Inhaled iloprost [24] is approved in Germany for IPAH in WHO
functional class III. It is administered via special nebulizers at
a dose of 2.5–5 μg, and inhalations have to be performed
6–9 times per day. Intravenous iloprost [32] is not approved
in Europe but represents the most widely used intravenous
prostanoid in Germany (see comment). Initiation of therapy and
continuous dose adjustments should only be carried out in PH
expert centers. As with other systemic prostanoids, there is a risk
of life-threatening catheter infections and other side effects that
typically occur during treatment with prostanoids (including
hypotension, ﬂushing, jaw pain and headaches, nausea, diarrhea,
etc.).
• Intravenous epoprostenol [15] was recently approved in Ger-
many, but is currently not widely used in this country.
• Treprostinil (inhaled, subcutaneous, intravenous, oral): oral tre-
prostinil and intravenous treprostinil are not approved in Ger-
many. Subcutaneous treprostinil [26] was not approved by the
EMA but by the French pharmaceutical regulatory agency. This
approval was adopted in Germany. Inhaled treprostinil [33] is
approved in the USA but not in Europe. The approval of inhaled
treprostinil in Germany is not expected in the near future.
Comment:
While in the ESC/ERS treatment algorithm, intravenous epoprostenol
is the only recommended therapy with the highest level of evidence
for patients in functional class IV and is also recommended with a
high level of evidence for patients in functional class III (besides oral
PDE-5 inhibitors, ERAs, and inhaled iloprost), this does not correspond
to the established pattern of use in Germany. Historically, this may be
explained by the fact that intravenous epoprostenol was only recently
approved in Germany (and all other prostanoids are not approved
for intravenous use) as well as the experience of local PH centers
that even patients who are in advanced stages (WHO functional
class IV) may be treated successfully with non-parenteral (usually
combination) therapies (see also comment on combination therapies).
Intravenous prostanoids (particularly intravenous iloprost) are gener-
ally only used in patients with impending or manifest right ventricular
failure. Intravenous iloprost is then uptitrated from an initial dose of
0.25–0.5 ng/kg/BW/min to a short- to medium-term target dose of 2–4
ng/kg/min. The use of intravenous prostanoids should strictly be lim-
ited to PH expert centers that have appropriate substantial experience
with such treatments. The choice of a permanently implanted central
venous access varies from center to center (Hickman catheter vs. port
systems) as does the preferred pump system. Intravenous prostacyclin
(epoprostenol) which is the only approved and preferably administered
prostanoid in other countries, is not widely used in Germany due to
the comparably high costs, the chemical instability with the need of
cooling and protection from light, and the associated limitations in
practical application.
Treatment with inhaled iloprost is approved in Europe for patients
with primary pulmonary hypertension (equivalent to IPAH and HPAH)
in functional class III. This deviates from the recommendations in
the ESC/ERS guidelines, the available data from the relevant phase
III study (AIR, which enrolled patients with a broader PAH spectrum
and patients with non-operable CTEPH) [24] as well as from the
pattern of use in Germany. Inhaled iloprost is frequently used analogue
to other targeted PAH drugs in patients with PAH. Regarding this
indication, there is consensus among the expert group. In light of the
elaborate administration as compared oral drugs (inhalation with a
special device, the variable duration [6–12 min/inhalation] and high
frequency of inhalations [6–9 times per day], inhaled iloprost is often
used in sequential combination therapies only after oral ERA and/or
PDE-5 inhibitors have already been used and the clinical improvement
was not satisfactory (see also section on treatment goals). With regard
to the approval situation it should be mentioned that unlike the
EMA, the FDA has approved inhaled iloprost for the treatment of PAH
in functional class III and IV. In Australia, inhaled iloprost is even
approved for patients with non-operable CTEPH, thus representing the
only approved PAH drug for this indication in a country with Western
health standards.
9. Combination therapy
Since there is currently no cure for PAH, and in the majority of
patients the treatment goals as deﬁned below cannot be achieved
or maintained by the use of monotherapy, a combination of the
above compounds has become the standard of care in many
PAH centers, although the long-term safety and eﬃcacy have not
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yet been amply explored. Numerous case series have suggested
that various drug combinations appear to be safe and effective.
In one series, a step-wise use of combination therapy according
to predeﬁned treatment goals was associated with an improved
outcome compared with a historical control group [34]. Results of
a few randomized controlled trials evaluating combination therapy
for PAH have been published, most of which have demonstrated
improved treatment results with a combination regimen [27,33,35].
The available data on combination therapy are still insuﬃcient and
there are many open questions, including the choice of combination
agents, the optimal timing (initial combination in naive patients
versus sequential combination according to the response to the ﬁrst
drug, when to switch, and when to combine. Therefore, no detailed
recommendations can be given at present. When combination
therapy is considered, patients should be treated within clinical
trials or registries whenever possible [1,2].
Comment:
Combination therapies using compounds from the three approved
drug classes, administered either sequentially or initially, constitute the
established long-term form of treatment for the majority of patients
with PAH. It is currently unclear if initial combination therapy should
be preferred to sequential combination therapy, especially in patients
with advanced stages of the disease (functional class III and IV). Since
there are little data available from randomized controlled trials thus
far, sequential combination therapy is mostly preferred in Germany at
present. Usually, patients with PAH are initially treated with one of
the approved oral targeted PAH drugs, i.e. either an ERA or a PDE-5
inhibitor. If the desired treatment goals are met within 3–6 months
(see stage-related treatment goals below), patients will remain on the
respective mono-therapy as long as prognostically relevant clinical
and hemodynamic values indicate that the disease is stabilized. If,
however, important treatment goals are either not met, or the patient
improved initially but deteriorates during the course of the treatment,
a complementary therapeutic agent will be added. The treatment
success will be re-evaluated after 3–6 months, and depending on the
test results, appropriate therapeutic decisions are being made. The ﬁnal
step in this common escalation sequence is the addition of intravenous
prostanoids (as mentioned above, the most commonly used compound
in Germany is intravenous iloprost).
Patients who do not show an adequate response to treatment
despite combination therapy should timely be referred to a transplant
center whenever possible. If patients are referred too late, and
atrial septostomy is considered and/or preparations for heart/lung
transplantation are initiated only after all available medical treatment
options have been exhausted there is almost no chance of reaching the
time of transplantation.
Data from the ﬁrst randomized controlled trials on the combined
use of targeted PAH drugs are available now, e.g. for subgroups in
pre-approval studies on inhaled treprostinil and oral tadalaﬁl (mostly
pretreatment with an ERA) [19,33] as well as the combination study
with intravenous epoprostenol and oral sildenaﬁl (PACES study) which
was planned exclusively as a combination therapy trial [27]. The latter
study was able to demonstrate a survival beneﬁt in patients receiving
combination therapy as compared to monotherapy with intravenous
epoprostenol. This has led to a paradigm shift in countries with
extensive use of epoprostenol (e.g. USA and France).
The indication for combination therapy must always be determined
on an individual basis. It is currently recommended in patients who do
not respond adequately to monotherapy. Due to the complex decision
making, safety reasons and pharmacoeconomic considerations, the
decision to initiate combination therapy should be reserved for expert
centers only.
10. Balloon atrial septostomy
Balloon atrial septostomy may improve survival in patients with
PAH, although there are no data on the value of this procedure in
patients who are treated with targeted PAH drugs, and the impact
on long-term survival has not been established in randomized
controlled trials. Atrial septostomy should be regarded as palliative
or bridging procedure to be performed only by centers with
experience in this method [1,2]. It is not indicated in stable patients
receiving drug treatment. Its therapeutic window is narrow, since
septostomy should also not be performed as emergency procedure
in patients with decompensated right heart failure (e.g. right atrial
pressure >20 mmHg, arterial O2 saturation at rest <80% on room
air) [1,2].
Comment:
In Germany, atrial septostomy is currently used as a very rare
treatment option in adults with PAH. There is a certain rationale for
patients who experience recurring syncopes despite extensive medical
therapy, but demonstrate compensated right heart function (e.g. right
atrial pressure <15 mmHg, no pericardial effusion, cardiac index >2
l/min/m2) and a peripheral oxygen saturation >95% (with or without
oxygen therapy). The mortality associated with this procedure depends
on the severity of the disease and the experience of the center, but is
reported to be up to 30%.
11. Transplantation
Double lung or heart–lung transplantation continues to be an
important therapeutic option for suitable patients who do not
respond suﬃciently to optimized medical therapy. PAH patients
with features of a poor prognosis proﬁle despite maximal treatment
should be referred for transplant listing well in advance. Patients
with PVOD or pulmonary capillary hemangiomatosis should be
listed for transplantation at diagnosis. The overall 5-year survival
rate following transplantation for PAH is 45–50%, with evidence of
continued good quality of life [1,2].
12. Treatment algorithm
An evidence-based treatment algorithm for patients with PAH
is provided in Fig. 1 [1,2]. These recommendations do not apply
to other forms of PH. The corresponding levels of evidence and
grades of recommendation are shown in Table 3 and refer to
scientiﬁc evidence and not to the approval status (Table 4). The
individual drug classes are listed in alphabetic order. Evidence for
the individual therapies mainly applies to IPAH and PAH associated
with connective tissue disease. Speciﬁc details listed below may
apply to other forms of PAH.
Comment:
Supervised rehabilitation is listed among supportive therapies. The
corresponding evidence was generated in Germany where all applicable
patients were treated in a single specialized center [5]. Therefore, the
available data does not allow generalization to all rehabilitation
facilities.
According to the ESC/ERS guidelines, i.v. epoprostenol is the only
recommended treatment for patients in WHO functional class IV.
However, epoprostenol has only recently been approved in Germany,
and the current level of experience is low, while other compounds (e.g.,
iloprost) are more frequently used.
13. Drug interactions
Signiﬁcant drug interactions involving the disease-speciﬁc ther-
apies for PAH must be taken into account. In accordance with
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Table 5
Potentially signiﬁcant drug interactions with PAH-targeted therapies (contraindicated or with proven interaction#.)
PAH drug Mechanism of interaction Interacting drug Interaction
Ambrisentan OATP inhibitor Cyclosporine Ambrisentan AUC increases 2-fold with concomitant administration,
therefore maximum administration of 5 mg/d ambrisentan.
CYP3A4 inhibitor Ketoconazole Clinically irrelevant increase of ambrisentan
Bosentan CYP3A4 inducer
OATP inhibitor
Cyclosporine This combination is contraindicated. Cyclosporine AUC falls 50%, bosentan
AUC increases 4-fold.
CYP3A4 inhibitor Erythromycin Bosentan AUC increases; may not require dose adjustment during short
co-medication.
CYP2C9 and CYP3A4 inhibitor Fluconazole Increase of bosentan AUC is expected, this combination is potentially
contraindicated.
CYP3A4 inducer + bile salt
pump (BSEP) inhibitor
Glibenclamide Risk of elevated aminotransferases. Potential decrease of the effect of
glibenclamide. This combination is contraindicated.
CYP3A4 inducer HMG CoA reductase inhibitors Simvastatin AUC reduces about 50%. Similar effects are expected with
lovastatin and atorvastatin. Cholesterol levels should be monitored.
CYP2C9 and 3A4 inducers Hormonal contraceptives Contraceptive AUC reduce about 30% (in individual cases even 60%).
Hormonal contraception unreliable.
CYP3A4 inhibitor Itraconazole This combination is potentially contraindicated.
CYP3A4 inhibitor Ketoconazole Bosentan AUC increases 2-fold.
CYP3A4 inhibitor,
Transporter inhibition
Lopinavir/Ritonavir This combination leads to transient 48-fold increase of bosentan
concentration, in steady-state to 5-fold increase. At the same time, protease
inhibitor AUCs decrease slightly (14–17%). Intensive monitoring of bosentan
effects is necessary.
Transporter inhibition Nevirapine Increase in hepatotoxicity is expected; this combination is not
recommended.
CYP2C9 and 3A4 inducers Rifampicin Bosentan AUC decreases by 58%, large variability. Need for dose adjustment
likely.
CYP3A4 inducer,
OATP inhibitor
Sildenaﬁl Sildenaﬁl AUC decreases by 63%, bosentan AUC increases by 50%. Dose
adjustment may not be required.
CYP3A4 inducer Tadalaﬁl Tadalaﬁl AUC decreases by 42%. No relevant change of bosentan AUC.
CYP2C9 inducer Warfarin Increases warfarin metabolism; intensiﬁed INR monitoring at the start of
treatment or adjustment of bosentan dose.
Sildenaﬁl Vasorelaxation Alpha blockers (doxazosin,
silodosin)
Pronounced reduction in blood pressure.
CYP3A4 inducer,
OATP inhibitor
Bosentan Sildenaﬁl AUC decreases by 63%, bosentan AUC increases by 50%. Dose
adjustment may not be required.
CYP3A4 inhibitor Cimetidine Sildenaﬁl AUC increases by 56%; usually no dose adjustment required.
CYP3A4 inhibitor Erythromycin Sildenaﬁl AUC increases by 183%. Probably no dose adjustment required.
CYP3A4 inhibitor Fluvoxamine Sildenaﬁl AUC increases by 40%, probably no dose adjustment required.
CYP3A4 inhibitor HIV protease inhibitors Ritonavir increases the sildenaﬁl AUC tenfold and is therefore
contraindicated. If the effect of saquinavir is less, dose adjustment is
required.
CYP3A4 inhibitor Itraconazole This combination is potentially contraindicated.
CYP3A4 inhibitor Ketoconazole Signiﬁcant increase of sildenaﬁl AUC; this combination is contraindicated.
Inhibition of cGMP breakdown Molsidomine, organic nitrates,
nicorandil
Signiﬁcant systemic hypotension. This combination is contraindicated.
CYP3A4 inhibitor Ritonavir Increase of sildenaﬁl AUC by 1100%; this combination is contraindicated.
Tadalaﬁl CYP3A4 inducer Bosentan Tadalaﬁl AUC decreases by 42%. No relevant change of bosentan AUC.
Vasorelaxation Doxazosin Increased reduction in blood pressure
CYP3A4 inhibitor Ketoconazole Twofold to fourfold increase of tadalaﬁl AUC.
Inhibition of cGMP breakdown Molsidomine, organic nitrates,
nicorandil
Signiﬁcant systemic hypotension. This combination is contraindicated.
CYP3A4 inducer Rifampicin Tadalaﬁl AUC decreases by 88%.
CYP3A4 inhibitor Ritonavir Twofold increase of tadalaﬁl AUC.
PDE inhibitors Theophylline Slight increase in heart rate.
# Since the ERA sitaxentan has been withdrawn from the market, this compound has been removed from the original ESC/ERS table.
the ESC/ERS guidelines, the most important known interactions of
targeted PAH drugs are compiled in Table 5 [1,2].
Comment:
In addition to the general approach of this recommendation, an
updated table of interactions is shown below that does not only
demonstrate already proven interactions and combinations without
interactions (Table 6) but also theoretical untested interactions that
can be expected and may be clinically relevant (Table 7).
• The proven interactions between some of the targeted PAH drugs
have lead to the deﬁnition of deﬁnite contraindications.
• So far, there are only single recommendations with regard to
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Table 6
Drug combinations for PAH-targeted therapies without interaction#.
PAH drug Interacting drug
Ambrisentan Digoxin
Ethinylestradiol
Norethisterone
Omeprazole
Sildenaﬁl
Tadalaﬁl
Warfarin
Bosentan Digoxin
Treprostinil
Sildenaﬁl Acetylsalicylic acid
Ambrisentan
Amlodipine
Atorvastatin
Azithromycine
Ethinylestradiol
Levonorgestrel
Magaldrat
Mg-/Al hydroxide
Tolbutamide
Warfarin
Tadalaﬁl Acetylsalicylic acid
Ambrisentan
Amlodipine
Digoxin
Enalapril
Lovastatin
Metoprolol
Midazolam
Tamsulosin
Warfarin
# Since the ERA sitaxentan has been withdrawn from the market, this compound
has been removed from the original ESC/ERS table.
possible dose adjustments of individual or several combination
partners or speciﬁc measures for risk minimization.
• As a rule, every dose adjustment associated with these (mostly)
dose-dependent interactions requires accurate monitoring and, if
necessary, a dose modiﬁcation.
• While there are well documented studies on interactions between
ERAs and warfarin, there is so far no published data on inter-
actions with phenprocoumon, representing the most commonly
used oral anticoagulant in Germany. In general and for the time
Table 7
Drug combinations for PAH-targeted therapies where interactions must be expected.)
PAH drug Mechanism of interaction Interacting drug Interaction
Bosentan CYP3A inducer Carbamazepine Need for dose adjustment likely
CYP3A4 inducer Phenobarbital Need for dose adjustment likely
CYP3A4 inducer Phenytoin Need for dose adjustment likely
Transporter interaction Sirolimus Increase of bosentan AUC is expected, this combination is not recommended.
Transporter interaction Tacrolimus Increase of bosentan AUC is expected, this combination is not recommended.
Sildenaﬁl CYP3A4 inducer Carbamazepine Decrease of sildenaﬁl AUC is expected
CYP3A4 inducer St. John’s wort Decrease of sildenaﬁl AUC is expected
CYP3A4 inducer Phenobarbital Decrease of sildenaﬁl AUC is expected
CYP3A4 inducer Phenytoin Decrease of sildenaﬁl AUC is expected
CYP3A4 inducer Rifampicin Decrease of sildenaﬁl AUC is expected
Tadalaﬁl Vasorelaxation Antihypertensive Variable increase in blood pressure reduction
CYP3A4 inducer Carbamazepine Decrease of tadalaﬁl AUC is expected
CYP3A4 inhibitor Clarithromycin Increase of tadalaﬁl AUC is expected
CYP3A4 inhibitor Erythromycin Increase of tadalaﬁl AUC is expected
CYP3A4 inhibitor Itraconazole Increase of tadalaﬁl AUC is expected
CYP3A4 inducer St. John’s wort Decrease of tadalaﬁl AUC is expected
CYP3A4 inducer Phenobarbital Decrease of tadalaﬁl AUC is expected
CYP3A4 inducer Phenytoin Decrease of tadalaﬁl AUC is expected
CYP3A4 inhibitor Saquinavir Increase of tadalaﬁl AUC is expected
AUC, area under the concentration–time curve (measure of exposure); cGMP, cyclic guanosine monophosphate; OATP, organic anion transporter protein; BSEP, bile salt
eﬄux pump; CYP, cytochrome P450 isoenzyme.
Potential contraindicated means that the manufacturer does not recommend this combination.
being, the recommendation regarding the combination of ERAs and
phenprocoumon should be equivalent to warfarin.
• Supervised coagulation self-control is recommended in suitable
patients.
• For a number of model compounds, interactions have been investi-
gated on a quality and quantity basis; empirically it is understood
that compounds with closely related mechanisms of interaction will
also interact even if this may have never been analyzed (Table 7).
• The proven pharmacokinetic interactions between targeted PAH
drugs have not yet led to a recommendation with regard to dose
adjustments of single or several combination partners because so
far no evident safety signals have occurred.
14. Deﬁnition of adequate clinical response
The proper assessment of adequate clinical response to medi-
cal therapy is essential for therapeutic decisions, particularly with
regard to the escalation treatment and the initiation of a combi-
nation therapy. According to the ESC/ERS guidelines, recommend
the initiation of a sequential combination therapy is recommended
if the clinical status of a patient is not satisfactory on monother-
apy (see Fig. 1; treatment algorithm). However, the judgement
of an unsatisfactory treatment effect may be challenging, and
the stage-related deﬁnition of inadequate response to therapy as
suggested in the ESC/ERS guidelines may be helpful (Table 8).
Furthermore, the guidelines recommend regular follow-up visits
and specify treatment goals (see article on non-invasive diagnosis
in this Supplement).
Comment:
Criteria of adequate clinical response are listed in Table 15 of the
original ESC/ERS guidelines (see also Fig. 2, in the article on “non-
Table 8
Deﬁnition of inadequate response to PAH treatments [1,2].
Inadequate clinical response for patients who were initially in WHO class II
or III:
1. Resulting clinical status deﬁned as stable and not satisfactory
2. Resulting clinical status deﬁned as unstable and deteriorating
Inadequate clinical response for patients who were initially in WHO class IV:
1. No rapid improvement to WHO class III or better
2. Resulting clinical status deﬁned as stable and not satisfactory
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invasive diagnosis” in this Supplement). However, they do not neces-
sarily apply to certain patient groups (e.g. congenital heart disease).
Therefore, treatment goals and consequently also adequate response
to treatment should be determined and evaluated according to the
condition of the individual patient and, if applicable, co-morbidities.
Therapeutic limitations and new developments
Despite the enormous progress that has been achieved in the area
of PAH during the last decade, it must be emphasized that this disease
is still not curable and that drug therapy for PAH must be continued
life-long. Despite the currently available therapies, morbidity and
mortality remain unsatisfactory. According to current registry data, the
annual mortality rate in PAH remains at approximately 10% [36,37].
Hence, the further improvement of medical treatment in PAH is highly
desirable. The German expert centers for PH are decisively involved in
the development of new agents, and for many patients enrollment in
clinical trials may be an option.
A number of novel agents is currently under clinical investigation.
These include stimulators of soluble guanylate cylcase (sGC) and
tyrosine kinase inhibitors (TKI). sGC stimulators act independently
of NO as well as synergistic with endogenous NO and thereby
promote pulmonary vasodilation [38,39]. An open-label phase II study
demonstrated that the sGC stimulator riociguat led to an improvement
of pulmonary hemodynamics and exercise tolerance in patients with
PAH and CTEPH [40]. In contrast to other drug classes, TKIs do not
have a vasodilating effect but act purely as antiproliferative agents.
They inhibit the activation of growth factor receptors (receptor tyrosine
kinases) which play a crucial role in the pathobiology of PAH [41–
43]. Current data of phase II and phase III studies indicate that the
TKI imatinib is effective in improving exercise tolerance, pulmonary
hemodynamics and right ventricular function in patients with severe
PAH and inadequate response to established therapies [44,45].
15. Speciﬁc PAH populations
15.1. PAH associated with congenital cardiac shunts
The complexity of diagnosis and therapy of patients with
congenital cardiac shunts render a detailed presentation impossible
at this point so that reference is made to the European guidelines
[1,2]. These patients should also be treated in specialized centers.
The recommendations are summarized in Table 9.
Comment:
Deﬁned treatment goals for Eisenmenger’s syndrome do not exist.
Only bosentan was investigated for the speciﬁc indication of
Eisenmenger’s syndrome (BREATHE-5 study) and showed signiﬁcant
improvements of pulmonary hemodynamics and exercise tolerance
without safety concerns [18]. This does not mean that other PAH drugs
are less effective or less safe.
Positive effects were also described for sildenaﬁl and epoprostenol in
small, uncontrolled studies [46–48], and for tadalaﬁl in a randomized
controlled study [49].
Current data from a retrospective analysis of 229 patients with
Eisenmenger’s syndrome demonstrated that targeted PAH therapy
in 68 patients who received either prostanoids and/or endothelin
receptor antagonists and/or PDE-5 inhibitors was associated with
a signiﬁcant improvement of survival [50]. Hence, targeted PAH
therapy is recommended in patients with Eisenmenger’s syndrome, the
respective classes of recommendation and levels of evidence are listed
in Table 9.
The available data on combination therapy is not suﬃcient to
provide detailed recommendations.
The recommendations for oral anticoagulant treatment in Eisen-
menger’s syndrome are controversial. Despite the bleeding tendency
of patients with Eisenmenger’s syndrome (coagulation disorders and
Table 9
Recommendations for PAH associated with congenital cardiac shunts [1,2].
Statement Class of recom-
mendation
Level of
evidence
The ERA bosentan is indicated in WHO-FC III
patients with Eisenmenger’s syndrome
I B
ERAs other than bosentan, PDE-5 inhibitors
and prostanoids should be considered in
patients with Eisenmenger’s syndrome
IIa C
In the absence of signiﬁcant hemoptysis, oral
anticoagulation treatment should be
considered in patients with pulmonary arterial
thrombosis or signs of heart failure
IIa C
The use of supplemental oxygen therapy
should be considered in cases in which it
produces a consistent increase in arterial
oxygen saturation and reduces symptoms
IIa C
If symptoms of hyperviscosity are present,
phlebotomy with isovolumic replacement
should be considered usually when hematocrit
is >65%
IIa C
Combination therapy may be considered in
patients with Eisenmenger’s syndrome
IIb C
The use of CCBs is not recommended in
patients with Eisenmenger’s syndrome
III C
concomitant thrombocytopenia), anticoagulation may be considered
in certain situations (e.g. atrial ﬁbrillation, thromboembolic events) if
there is no relevant hemoptysis present. In this case, the adjustment
of coagulation requires expert knowledge. Speciﬁc tests are needed
to determine the coagulation parameters in erythrocytosis and a
hemoglobin level >65%.
Phlebotomies should be avoided in general. The indication for
phlebotomy must be determined according to strict speciﬁcations.
Indications are given almost only in symptomatic erythrocytosis (HCT
markedly exceeding 65%) and neurological symptoms if exsiccosis or
hypovolemia have been ruled out. It is also important to provide
adequate volume replacement. Repeated phlebotomies lead to iron
deﬁciency which may worsen the rheologic properties in the microvas-
cular system. In case of iron deﬁciency that has been documented
through laboratory tests (including the determination of transferrin,
ferritin, soluble transferrin receptor), low-dose(!) iron replacement
is recommended (caution: exacerbated increase of hemoglobin and
hematocrit!).
16. PAH associated with connective tissue disease
PAH occurs in 5–15% of patients with systemic sclerosis, 5–
10% of patients with mixed connective tissue disease, and 2–
5% of patients with systemic lupus erythematosus (SLE) [51,52].
Diagnosis and therapy of PAH in these patients largely follows
the above-mentioned principles for IPAH, however screening is
recommended in asymptomatic patients with systemic sclerosis
or mixed connective tissue disease (Table 10). The signiﬁcance
of additional immunosuppressive or immunomodulatory therapies
depends on the underlying disease. For PAH associated with
scleroderma, this approach is believed to be without effect and
is not recommended, while immunosuppressive treatment in SLE
and PAH has been reported to be successful. Patients with PAH
associated with mixed connective tissue disease usually show the
same response as scleroderma patients but, in individual cases, may
also beneﬁt from immunosuppressive therapy.
Comment:
In patients with collagenosis (e.g. SLE, MCTD), the possibility of
immunosuppressive therapy should be evaluated within the framework
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Table 10
Recommendations for PAH associated with connective tissue disease [1,2].
Statement Class of recom-
mendation
Level of
evidence
In patients with PAH associated with CTD, the
same treatment algorithm as in patients with
IPAH is recommended
I A
Echocardiographic screening for the detection
of PH is recommended in symptomatic *
patients with scleroderma spectrum of diseases
I B
Echocardiographic screening for the detection
of PH is recommended in symptomatic *
patients with all other CTDs
I C
Right heart catheterization is indicated in all
cases of suspected PAH associated with CTD,
in particular if speciﬁc drug therapy is
considered
I C
Oral anticoagulation should be considered on
an individual basis
IIa C
Echocardiographic screening for the detection
of PH may be considered in asymptomatic *
patients with the scleroderma spectrum of
diseases
IIb C
CTD, connective tissue disease; PH, pulmonary hypertension; PAH, pulmonary
arterial hypertension (group I).
* Symptoms of pulmonary hypertension or right ventricular failure.
Table 11
Recommendations for PAH associated with portal hypertension [1,2].
Statement Class of recom-
mendation
Level of
evidence
Echocardiographic screening for the detection
of PH is recommended in symptomatic
patients with liver diseases and/or in
candidates for liver transplantation
I B
In patients with PAH associated with portal
hypertension, the same treatment algorithm as
in patients with IPAH should be considered,
taking into consideration comorbidities
IIa C
Anticoagulation is not recommended in
patients with increased risk of bleeding
III C
Signiﬁcant PAH is a contraindication to liver
transplantation if mean PAP ≥35 mmHg
and/or PVR ≥250 dyn s cm−5
III C
of interdisciplinary cooperation. Patients with PAH associated with
systemic sclerosis generally do not respond to immunosuppressive
therapy.
16.1. PAH associated with portal hypertension
Portopulmonary hypertension (PoPH) is deﬁned as the occur-
rence of PAH in patients with portal hypertension. The incidence of
PoPH in patients with liver cirrhosis is approximately 0.5–1% [1,2].
The recommendations of the ESC/ERS guidelines are summarized in
Table 11. Echocardiographic screening to rule out right ventricular
load should be performed in patients who are evaluated for liver
transplantation, since survival after transplantation depends on the
presence and extent of PH. There are no data from controlled
studies on the treatment of PoPH. The same treatment algorithm
as in IPAH is recommended, however, taking co-morbidities into
consideration [1,2].
Comment:
Smaller case studies indicate the eﬃcacy and safety of PAH drugs
for the treatment of PAH associated with portal hypertension, but there
are no data from a randomized controlled trial. This does not mean
Table 12
Recommendations for PAH associated with HIV infection [1,2].
Statement Class of recom-
mendation
Level of
evidence
Echocardiography is indicated in patients with
unexplained dyspnea to detect HIV-related
cardiovascular complications
I B
In patients with PAH associated with HIV
infection, the same treatment algorithm as in
patients with IPAH should be considered,
taking into consideration co-morbidities and
drug–drug interactions
IIa C
Anticoagulation is not recommended in
patients with increased risk of bleeding
III C
that PAH drugs are not effective or unsafe in this case. In patients with
Child A cirrhosis, positive experiences with bosentan, sildenaﬁl, and
ambrisentan have been published [53–56]. ERAs are contraindicated
in advanced liver disease, so that PDE-5 inhibitors and/or prostanoids
are mostly used in this situation. In rare individual cases, combined
lung–liver transplantation may be considered in treatment refractory
cases [57].
In candidates for liver transplantation, it is important to distinguish
between portopulmonary hypertension and the hepatopulmonary syn-
drome. In the latter case, the indication for transplantation may be
given if the mean PAP is ≥35 mmHg within the scope of hepatic
hypercirculation.
16.2. PAH associated with HIV infection
Approximately 0.5% of HIV-infected patients develop PAH [58].
In these patients, the diagnostic work-up and treatment strategies
are largely based on the above-mentioned recommendations (see
Table 12). Positive experiences have been reported with bosentan
and sildenaﬁl. In some but not all cases, the use of antiretroviral
therapy had a positive effect on the course of PAH. Potential
interactions between PAH-speciﬁc drugs and antiretroviral therapy
must be taken into account (see section on drug interactions). This
applies especially to the combination of sildenaﬁl with HIV protease
inhibitors (see Table 5).
Comment:
Smaller case studies indicate the eﬃcacy and safety of targeted PAH
drugs – especially bosentan [59,60] and sildenaﬁl [61,62]. However, for
the speciﬁc indication PAH associated with HIV infection, there are no
data from randomized controlled trials. This does not mean that PAH
drugs are not effective or unsafe in this case.
17. Pulmonary veno-occlusive disease (PVOD)
Since PVOD is usually very diﬃcult to diagnose, one of the
most important criteria for the potential presence of PVOD is
the insuﬃcient response or clinical worsening on targeted PAH
treatment. There is still no medical therapy for PVOD and the
prognosis is particularly poor, so that patients should be referred to
a transplant center as soon as the corresponding tentative diagnosis
is established (Table 13).
18. Speciﬁc pediatric aspects
The complexity of diagnosis and therapy in different types of
PAH and in different age groups constitutes that children with PAH
should be treated exclusively at specialized expert centers. The
special aspects in children with PAH are considered in the ESC/ERS
guidelines only to the extent that they are valid independent
of age. The treatment recommendations currently applicable for
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Table 13
Recommendations for patients with pulmonary veno-occlusive disease [1,2].
Statement Class of recom-
mendation
Level of
evidence
Referral of patients with PVOD to a transplant
center for evaluation is indicated as soon the
diagnosis is established
I C
Patients with PVOD should be managed only
in centers with extensive experience in PAH
due to the risk of lung edema after the
initiation of PAH-speciﬁc drug therapy
IIa C
Table 14
Recommendations for pediatric PAH [1,2].
Statement Class of recom-
mendation
Level of
evidence
The PH diagnostic work-up proposed for
adults should also be considered in children
IIa C
The PAH therapeutic algorithm proposed for
adults should also be considered in children
IIa C
adults have been largely adopted for the treatment of children
with PAH. There is, however, much less available data from
randomized controlled studies in children than in adults. Regarding
the recommendation to use the same diagnostic and therapeutic
algorithms as for adults, there is a class IIA recommendation, and
the level of evidence is C (Table 14).
Comment and speciﬁc recommendations for children:
• When the available data from clinical trials and the approval status
are considered, the diagnostic and therapeutic algorithms suggested
for adults cannot be applied in children without modiﬁcation. For
example, the 6-minute walking test is neither standardized nor
has it been prospectively evaluated in children (see article on
non-invasive diagnosis in this Supplement).
• Chronic thromboembolic disease plays a minor role in children,
while congenital heart disease represents the predominant form of
PH.
• Recent studies have documented that the use of available drug
therapies (e.g. i.v. epoprostenol, bosentan, sildenaﬁl) either as
mono- or as combination therapy lead to improved survival in
children as compared to historical untreated populations [63,64].
• The ERA bosentan is approved for children, as it has been specif-
ically investigated in children [65–67]. Based on the available
information, bosentan is approved from the age of 2 years and is
available in a special pharmaceutical form of 32-mg tablets that
can be quartered (initial dose for the ﬁrst 4 weeks: 2 mg/kg/d in 2
single doses, target dose: 4 mg/kg/d in 2 single doses). This does not
mean that other ERAs are less effective or less safe. Because of the
available data and the approval status, however, they should only
be used in justiﬁed exceptions.
• The PDE-5 inhibitor sildenaﬁl is also approved in children at the age
between 1 and 17 years (1.5–4.5 mg/kg/d in 3 single doses). It may
be used as monotherapy or in combination with other PAH drugs.
The warning letter addressing higher dosages has been addressed
above.
• Inhaled iloprost is usually only used in cases of treatment escalation
when oral therapies are not suﬃciently effective. In Germany,
no intravenous prostanoid is currently approved for the use in
children. In selected cases, epoprostenol (initial dose 2 ng/kg/min,
dose increase according to therapeutic effect) or iloprost (initial
dose 0.5 ng/kg/min) may be used.
• In children with IPAH who demonstrate a favourable response dur-
ing acute vasoreactivity testing, CCBs (amlodipine 0.1–0.5 mg/kg/d,
nifedipine 1–2 mg/kg/d) are used as in adults. Because of the higher
vasoreactivity rate in children that correlates negatively with age
and the therapeutic consequences, acute vasoreactivity testing is
recommended in children with IPAH.
• The treatment of PAH associated with congenital heart disease
(postoperative, Eisenmenger’s syndrome, etc.) basically equals that
of IPAH.
• During childhood, there are a number of speciﬁc diseases with
increased pulmonary vascular resistance for which a targeted PAH
therapy may be considered on an individual basis. These include
infants with bronchopulmonary dysplasia or children with univen-
tricular heart and passive pulmonary blood ﬂow (Fontan circula-
tion). Since data from clinical studies are lacking for these diseases,
treatment decisions have to be based on empiric experience in such
cases.
19. Treatment in referral centers for pulmonary hypertension
Due to the complex issues and often diﬃcult treatment deci-
sions, the ESC/ERS guidelines recommend to refer patients with
suspected pulmonary hypertension to a specialized center. This is
to ensure the correct diagnosis of patients and the prescription
of speciﬁc PAH drugs that are appropriate to the indication and
meet the needs of the individual patients. PH centers are able to
carry out the diagnosis and therapy of all or nearly all forms of PH
independently and according to guidelines. The requirements listed
in the ESC/ERS guidelines are presented in Table 15.
Comment:
In Germany there is an independent discussion about the deﬁnition
of a referral center for pulmonary hypertension. To some extent,
the criteria are set considerably lower than those stipulated in the
European guidelines. The authors believe that the criteria listed in
the European guidelines constitute meaningful speciﬁcations that help
deﬁne a PH expert center.
More detailed speciﬁcations are required for referral centers man-
aging rare subgroups, such as children and patients with congenital
heart disease.
It is recommended to promote the development of network struc-
tures aiming at interdisciplinary expertise in PH. This includes the
close cooperation with patient organizations (in Germany “pulmonale
hypertonie e.V. [phev]”) (see general section).
Table 15
Recommendations for a pulmonary hypertension referral center [1,2].
Statement Class of recom-
mendation
Level of
evidence
Referral centersare required to provide care by
a multiprofessional team (cardiology and
respiratory medicine physicians, clinical nurse
specialists, radiologists, psychological and
social work support, appropriate on-call
expertise)
I C
Referral centers are required to have direct
links and quick referral patterns to other
services (such as CTD service, family planning
service, PEA service, lung transplantation
service, adult congenital heart disease service)
I C
A referral center should follow at least 50
patients with PAH or CTEPH and should
receive at least two new referrals per month
with documented PAH or CTEPH
IIa C
Referral centers should perform at least 20
vasoreactivity tests in PAH patients per year
IIa C
Referral centers should participate in
collaborative clinical research in PAH, which
includs phase II and phase III clinical trials
IIa C
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Contact address of the German patient organization:
“pulmonale hypertonie e.V. (phev)”,
Bruno Kopp (National Chairman)
Wormser Str. 20; D-76287 Rheinstetten
Internet: http://www.phev.de, e-mail: info@phev.de
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